-+ 0.00%
-+ 0.00%
-+ 0.00%

AtaiBeckley To Initiate Phase 3 Trial Of BPL‑003 (Mebufotenin Benzoate Nasal Spray) In Q2 2026 Following End-Of-Phase 2 Meeting With The FDA, Cash Runway Reaffirmed Through The Planned Early-2029

Benzinga·03/10/2026 10:06:14
Listen to the news
  • BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression
  • Cash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studies
  • Commercial readiness advancing with scalable treatment model aligned to existing interventional psychiatry workflows
  • Continued pipeline progress, including positive Phase 2a results for EMP‑01 and expected Phase 2 topline for VLS-01 in H2 2026